The N Myc Proto Oncogene Protein pipeline drugs market research report outlays comprehensive information on the N Myc Proto Oncogene Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the N Myc Proto Oncogene Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Neuroblastoma, and Solid Tumor. It also reviews key players involved in N Myc Proto Oncogene Protein targeted therapeutics development with respective active and dormant or discontinued products.
The N Myc Proto Oncogene Protein pipeline targets constitutes close to eight molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 1, 5, and 2 respectively.
N Myc Proto Oncogene Protein overview
N-Myc proto-oncogene protein is a protein encoded by a gene MYCN. This protein is also known as N-Myc or basic helix-loop-helix protein 37 (bHLHe37). Amplification of MYCN gene is associated with a variety of tumors, most notably neuroblastomas.
For a complete picture of N Myc Proto Oncogene Protein’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
